Literature DB >> 22797697

VEGFR-3 is expressed on megakaryocyte precursors in the murine bone marrow and plays a regulatory role in megakaryopoiesis.

Wilko Thiele1, Jaya Krishnan, Melanie Rothley, Debra Weih, Diana Plaumann, Vanessa Kuch, Luca Quagliata, Herbert A Weich, Jonathan P Sleeman.   

Abstract

VEGFR-3 is a transmembrane receptor tyrosine kinase that is activated by its ligands VEGF-C and VEGF-D. Although VEGFR-3 has been linked primarily to the regulation of lymphangiogenesis, in the present study, we demonstrate a role for VEGFR-3 in megakaryopoiesis. Using a human erythroleukemia cell line and primary murine BM cells, we show that VEGFR-3 is expressed on megakaryocytic progenitor cells through to the promegakaryoblast stage. Functionally, specific activation of VEGFR-3 impaired the transition to polyploidy of CD41+ cells in primary BM cultures. Blockade of VEGFR-3 promoted endoreplication consistently. In vivo, long-term activation or blockade of VEGFR-3 did not affect steady-state murine megakaryopoiesis or platelet counts significantly. However, activation of VEGFR-3 in sublethally irradiated mice resulted in significantly elevated numbers of CD41+ cells in the BM and a significant increase in diploid CD41+ cells, whereas the number of polyploid CD41+ cells was reduced significantly. Moreover, activation of VEGFR-3 increased platelet counts in thrombopoietin-treated mice significantly and modulated 5-fluorouracil-induced thrombocytosis strongly, suggesting a regulatory role for VEGFR-3 in megakaryopoiesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22797697     DOI: 10.1182/blood-2011-09-376657

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies.

Authors:  Christian A Di Buduo; Lindsay S Wray; Lorenzo Tozzi; Alessandro Malara; Ying Chen; Chiara E Ghezzi; Daniel Smoot; Carla Sfara; Antonella Antonelli; Elise Spedden; Giovanna Bruni; Cristian Staii; Luigi De Marco; Mauro Magnani; David L Kaplan; Alessandra Balduini
Journal:  Blood       Date:  2015-01-09       Impact factor: 22.113

2.  Improved quantitative analysis of primary bone marrow megakaryocytes utilizing imaging flow cytometry.

Authors:  Lisa M Niswander; Kathleen E McGrath; John C Kennedy; James Palis
Journal:  Cytometry A       Date:  2014-01-16       Impact factor: 4.355

3.  Platelet Count is Associated with the Rate of Lymph Node Metastasis in Lung Adenocarcinoma.

Authors:  Cheng-Hao Qu; Tong Li; Zhan-Peng Tang; Xi-Rui Zhu; Jing-Yi Han; Hui Tian
Journal:  Cancer Manag Res       Date:  2020-10-07       Impact factor: 3.989

4.  Administration of nicotinamide does not increase platelet levels in mice.

Authors:  Iwona M Konieczna; Swapna Panuganti; Teresa A DeLuca; E Terry Papoutsakis; Elizabeth A Eklund; William M Miller
Journal:  Blood Cells Mol Dis       Date:  2012-12-21       Impact factor: 3.039

5.  Inhibition of VEGFR-3 activation in tumor-draining lymph nodes suppresses the outgrowth of lymph node metastases in the MT-450 syngeneic rat breast cancer model.

Authors:  Luca Quagliata; Sandra Klusmeier; Natascha Cremers; Bronislaw Pytowski; Alfred Harvey; Ronald J Pettis; Wilko Thiele; Jonathan P Sleeman
Journal:  Clin Exp Metastasis       Date:  2013-12-31       Impact factor: 5.150

6.  VEGF-C protects the integrity of the bone marrow perivascular niche in mice.

Authors:  Shentong Fang; Shuo Chen; Harri Nurmi; Veli-Matti Leppänen; Michael Jeltsch; David Scadden; Lev Silberstein; Hanna Mikkola; Kari Alitalo
Journal:  Blood       Date:  2020-10-15       Impact factor: 22.113

7.  Breast Lesions Diagnosed as Ductal Carcinoma In Situ by Ultrasound-Guided Core Needle Biopsy: Risk Predictors for Concomitant Invasive Carcinoma and Axillary Lymph Node Metastasis.

Authors:  Yanbiao Liu; Xu Wang; Ang Zheng; Xinmiao Yu; Zining Jin; Feng Jin
Journal:  Front Oncol       Date:  2021-09-10       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.